title: Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
abstract: OBJECTIVE
  To evaluate the effectiveness and safety of olopatadine hydrochloride and to determine its optimal concentration and the onset and duration of action for treating allergic conjunctivitis. Olopatadine is a new topical ophthalmic antiallergic agent that demonstrates activity as both an antihistamine and a mast cell stabilizer. Two double-masked, randomized, placebo-controlled, contralateral eye comparison studies were conducted using the conjunctival allergen challenge model.
  
  
  METHODS
  A total of 169 subjects received 0.05% or 0.1% olopatadine. Study subjects were healthy adult men and women with a history of active allergic conjunctivitis within the previous two seasons but not receiving current treatment. With an allergen dose that produced signs and symptoms of allergic conjunctivitis at visits 1 and 2, the conjunctival allergen challenge was performed 27 minutes after study drug administration at the third visit (onset-of-action challenge) and at 8 hours after study drug administration at the fourth visit (duration-of-action challenge). Olopatadine was administered in one eye and placebo in the opposite eye. Itching and redness were scored for both eyes at 3, 10, and 20 minutes after the conjunctival allergen challenge.
  
  
  RESULTS
  Both 0.05% and 0.1% concentrations of olopatadine were significantly (P < .05) more effective than placebo in inhibiting itching and redness at all evaluations when administered 27 minutes or 8 hours before the conjunctival allergen challenge. There were no serious or drug-related ocular or nonocular adverse events in either study.
  
  
  CONCLUSIONS
  These findings demonstrate the rapid and prolonged (at least 8 hours) ocular antiallergic action of olopatadine.
authors.affiliation: Ophthalmic Research Associates, Inc, North Andover, Massachusetts 01845, USA.
authors.forename: M B
authors.initials: MB
authors.lastname: Abelson
authors.forename: L
authors.initials: L
authors.lastname: Spitalny
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000485:Allergens / Q000009:adverse effects*; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003228:Conjunctiva / Q000187:drug effects; D003233:Conjunctivitis, Allergic / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D003990:Dibenzoxepins / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D000069605:Olopatadine Hydrochloride; D009883:Ophthalmic Solutions; D011058:Pollen / Q000009:adverse effects*; D012449:Safety
chemical_list: D000485:Allergens; D018926:Anti-Allergic Agents; D003990:Dibenzoxepins; D006634:Histamine H1 Antagonists; D009883:Ophthalmic Solutions; D000069605:Olopatadine Hydrochloride